Latest for Medullary Thyroid Cancer
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
More about Medullary Thyroid Cancer
About 75% of MTC cases are sporadic (no family history), while 25% are hereditary, caused by activating mutations in the RET proto-oncogene and associated with Multiple Endocrine Neoplasia type 2 (MEN 2A and MEN 2B) or Familial MTC (FMTC). Surgery (total thyroidectomy with lymph node dissection) is the primary treatment for localized disease.
Keep reading about Medullary Thyroid Cancer
For advanced or metastatic MTC, the treatment landscape changed dramatically with the FDA approval of selective RET inhibitors. Selpercatinib (Retevmo, Eli Lilly) received full FDA approval in September 2024 after the phase 3 LIBRETTO-531 trial showed superior progression-free survival compared to older multikinase inhibitors.
The older multikinase inhibitors vandetanib (Caprelsa, approved 2011) and cabozantinib (Cometriq, Exelixis, approved 2012) remain available but carry broader side-effect profiles. Pralsetinib (Gavreto) was previously approved for RET-altered MTC under accelerated approval, but that indication was voluntarily withdrawn in 2023 when the confirmatory trial proved infeasible.
RET mutation testing (germline for hereditary cases, somatic via NGS panels for sporadic advanced disease) is essential to guide treatment selection.
What are the symptoms of Medullary Thyroid Cancer?
These are common symptoms of Medullary Thyroid Cancer, and how strong they are varies from person to person.
- A lump or nodule in the neck, often painless
- Hoarseness or voice changes if the tumor presses on the recurrent laryngeal nerve
- Difficulty swallowing (dysphagia)
- Diarrhea, sometimes severe, from calcitonin excess
- Flushing in advanced disease
- Bone pain, cough, or shortness of breath if the cancer has spread
Who gets Medullary Thyroid Cancer?
Sporadic MTC typically presents between ages 40-60 and affects males and females equally. Hereditary MTC (25% of cases) is caused by germline RET proto-oncogene mutations and can present much earlier, sometimes in childhood. All populations are affected with no known ethnic or racial predisposition.
Risk factors for sporadic MTC are not well defined. Family history of MTC or MEN 2 syndromes is the strongest risk factor for hereditary disease.
Next steps: find trials you might fitsee approved treatmentsget help payingget alerts
Which medicines are FDA-approved for Medullary Thyroid Cancer?
There are currently 3 FDA-approved medications for Medullary Thyroid Cancer.
Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.
How to get help paying for Medullary Thyroid Cancer treatment
Charity funds and drugmaker programs for Medullary Thyroid Cancer, checked at the source.
- From a charity · The Assistance FundThyroid Cancer fundWaitlist
Pays for: Copays, coinsurance, deductibles and other health-related expenses.
- Retevmo (Selpercatinib) · Retevmo Savings Card
- Caprelsa (Vandetanib) · CAPRELSA Access Support
- Cometriq (Cabozantinib) · Exelixis Access Services (EASE)
Every program and fund for Medullary Thyroid Cancer, by insurance →
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for Medullary Thyroid Cancer
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
The RET gene page lists every condition Orphanet links to the gene and the open trials that name it.
Finding labs...
Trusted Medullary Thyroid Cancer resources
Reputable organizations and medical references for learning more about Medullary Thyroid Cancer, including disease registries, foundation resources, and clinical guidelines.